Duke Researchers Propose Combination Therapy for PIK3CA-Mutant Breast Cancer

Dec 14, 2016

|

NEW YORK (GenomeWeb) – A Duke University team has found early evidence that breast cancer cases marked by PIK3CA mutations may be vulnerable to combined treatments targeting programmed cell death and mTOR signaling pathways.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Spiders and Scorpions, Oh My!

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

Keep It Secret

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Page Joins Chronic Disease Startup

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

This Week in Cell

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

Featured White Papers

Bionano Genomics’ Next-Generation Mapping Identifies Large Structural Variants in Cancer and Genetic Disorders

Albumin & IgG Removal Reference Applications

Compatibility of POLYVIEW IHC Detection Reagents and HIGHDEF IHC Chromogens with Automated IHC Slide Stainers

Sep

20

Featured Webinar

Latest Advances in Tumor Genomic Profiling for Challenging Samples

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep

21

Featured Webinar

Processing Challenging Tumor Samples via Automated Tissue Dissection and Extraction-Free Library Prep

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Main menu